Start Free Trial
Pricing
Log In
Log In
Upgrade browser for full Crunchbase experience. You're accessing Crunchbase in a browser that is no longer supported.
Learn More
MindMed Logo
MindMed Growth Score
49
CB Rank
194652
Heat Score
15
MindMed provides psychedelic-inspired medicines and therapies for substance abuse disorders and other mental illnesses.
Founded
obfuscation
PublicPost-IPO Equity New York, New York, United States101-250 www.mindmed.co
Biotechnology
Health Care
Pharmaceutical
Therapeutics
Overview

MindMed
Total Funding
obfuscation
Growth Score
49
Heat Score
15

Total Funding
obfuscation
obfuscation
Post-IPO Equity raised
obfuscation
Growth Score49
-14 pts
in past quarter
Heat Score 15
-12 pts
in past quarter

Company Performance Metrics

Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Learn More >
See more interactive data and historical milestones on desktop for the best experience

About MindMed

CB Rank
194652
MindMed provides psychedelic-inspired medicines and therapies for substance abuse disorders and other mental illnesses.
Founded
obfuscation
PublicPost-IPO Equity New York, New York, United States101-250 www.mindmed.co
Biotechnology
Health Care
Pharmaceutical
Therapeutics

Funding Rounds

Post-IPO Equity
OBF
in
obfuscation
Post-IPO Equity
OBF
in
obfuscation
Post-IPO Equity
OBF
in
obfuscation

Key People

Details

Legal Name Mind Medicine, Inc.
Operating Status Active
Stock Symbol  NASDAQ:MNMD
Company Type For Profit
Founders  Robert Barrow
About the Company
MindMed provides psychedelic-inspired medicines and therapies for substance abuse disorders and other mental illnesses. The company is assembling a compelling drug development pipeline of innovative treatments based on psychedelic substances including Psilocybin, LSD, MDMA, DMT, and an Ibogaine derivative, 18-MC.
Contact Email info@mindmed.co
Predictions & Insights

Growth Insight

See this Growth Insight
MindMed is
Lorem
 to be growing
Top Contributing Factors
Recently Raised Funding

Products & Services

MM120 Orally Disintegrating Tablet (ODT)
A pharmaceutically optimized LSD formulation designed to treat brain health disorders such as generalized anxiety disorder and major depressive disorder.
MM402 (R(-)-MDMA)
An investigational compound under development to improve social and communication skills in individuals with autism spectrum disorder.

Research & Development

MindMed is

obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
...

Unlock More with Crunchbase Pro
  • Full access to financial & funding data on unlimited profiles
  • Export up to 2k results/month for analysis
  • Track market signals on competitors, products, and R&D
  • Preview private company insights and predictions
Financials

Company Funding

Total Funding Amount 
obfuscation
Number of Funding Rounds 13
Unlock company funding data, including rounds, dates, amounts, and investors.
Announced Date  
Transaction Name  
Number of Investors  
Money Raised  
Lead Investors  
Funding Type  
obfuscation
Post-IPO Equity - MindMed Logo
Post-IPO Equity - MindMed
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - MindMed Logo
Post-IPO Equity - MindMed
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - MindMed Logo
Post-IPO Equity - MindMed
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - MindMed Logo
Post-IPO Equity - MindMed
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - MindMed Logo
Post-IPO Equity - MindMed
—
obfuscation
— Post-IPO Equity

Funding Rounds

Total Funding Amount 
obfuscation
Number of Funding Rounds 13
Unlock company funding data, including rounds, dates, amounts, and investors.
Announced Date  
Transaction Name  
Number of Investors  
Money Raised  
Lead Investors  
Funding Type  
obfuscation
Post-IPO Equity - MindMed Logo
Post-IPO Equity - MindMed
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - MindMed Logo
Post-IPO Equity - MindMed
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - MindMed Logo
Post-IPO Equity - MindMed
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - MindMed Logo
Post-IPO Equity - MindMed
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - MindMed Logo
Post-IPO Equity - MindMed
—
obfuscation
— Post-IPO Equity

Investors

Unlock company funding data, including rounds, dates, amounts, and investors.
Investor Name  
Lead Investor  
Funding Round  
Partners  
Octagon Capital Advisors Logo
Octagon Capital Advisors
—
Post-IPO Equity - MindMed Logo
Post-IPO Equity - MindMed
—
Octagon Capital Advisors Logo
Octagon Capital Advisors
—
Post-IPO Equity - MindMed Logo
Post-IPO Equity - MindMed
—
Octagon Capital Advisors Logo
Octagon Capital Advisors
—
Post-IPO Equity - MindMed Logo
Post-IPO Equity - MindMed
—
Octagon Capital Advisors Logo
Octagon Capital Advisors
—
Post-IPO Equity - MindMed Logo
Post-IPO Equity - MindMed
—
Octagon Capital Advisors Logo
Octagon Capital Advisors
—
Post-IPO Equity - MindMed Logo
Post-IPO Equity - MindMed
—

Investments

Number of Acquisitions 1

Investment Breakdown

Number of Acquisitions 1
Market Intelligence
People
View Profiles & Contacts
Headcount 101-250 Employee Profiles 12 Board Members and Advisors 8 Contacts 62

Employee Profiles

Board Members and Advisors

News

News and Press

News•Apr 18, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•Mar 4, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•Jan 12, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•Nov 24, 2025
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
Access a complete feed of recent news and press, from product launches to leadership changes.
Technology
View Tech Report

Monthly Web Visits

450
637.7%
 in past month

IT Spend

$417.6KThis year, MindMed is projected to spend $417.6K on IT, according to Aberdeen.

Interest Signals

TopicSurge Score
Meta Platforms, Inc. Logo
Meta Platforms, Inc.
97
Clinical Services Logo
Clinical Services
94
Unemployment Logo
Unemployment
91

Actively Used Products

10MindMed uses 10 technology products and services including HTML5, jQuery, and  Wordpress, according to G2 Stack.

Active Website Tech Count

13MindMed is actively using 13 technologies for its website, according to BuiltWith. These include HSTS, Apache, and  U.S. Server Location.

Total IP

32The intellectual property of MindMed includes 30 registered patents primarily in the 'Medical Or Veterinary Science; Hygiene' category, according to IPqwery. Additionally, MindMed has registered 2 trademarks with the most popular class being 'Household or kitchen utensils, containers and materials; glassware; porcelain; earthenware', according to IPqwery.
Sub-Organizations
Frequently Asked Questions

Where is MindMed's headquarters? MindMed is located in New York, New York, United States.Who invested in MindMed? MindMed has 21 investors including Octagon Capital Advisors and  Deep Track Capital.When was the last funding round for MindMed? MindMed closed its last funding round on
obfuscation
from a Post-IPO Equity round.Who are MindMed's competitors? Alternatives and possible competitors to MindMed may include Alto Neuroscience, MapLight Therapeutics, and  Gilgamesh Pharmaceuticals.How much funding has MindMed raised to date? MindMed has raised
obfuscation
.
Who We Are
What We Do
Helpful Links
AI Content may contain mistakes and is not legal, financial or investment advice. Learn more.
Terms of Service | Privacy Policy | Sitemap | © 2026 Crunchbase Inc. All Rights Reserved.
(9fd75b2 1)
|